AbbVie Shares Plummet After Schizophrenia Drug Trials Disappoint
TL;DR
AbbVie announced that its Phase 2 EMPOWER trials for emraclidine, a potential treatment for schizophrenia, did not meet the primary endpoint of significantly reducing symptoms compared to placebo. Despite the setback, emraclidine was well-tolerated, and AbbVie remains committed to advancing its neuroscience pipeline. The company continues to analyze the data to determine future steps in developing treatments for psychiatric and neurological disorders.
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia AbbVie
- Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure Investor's Business Daily
- AbbVie Stock Falls on Schizophrenia Drug Study Failure The Wall Street Journal
- AbbVie's closely watched schizophrenia drug fails two studies, shares slide Reuters
- AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials Bloomberg
Want the full story? Read the original reporting
Read on AbbVie